HAI-ROBOTICS
Hai Robotics ("Hai") has joined forces in the inauguration of L'Oréal's SMART Fulfillment Center in Suzhou, China. Located inside Suzhou Industrial Park, this fulfillment center signals Hai's ongoing commitment to support its customers on every step of their warehousing journey with technical expertise, quality service and prompt delivery.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240512209916/en/
From left to right: Shengdong Xu, Chief Technology Officer (Hai Robotics); Richie Chen, Founder and Chief Executive Officer (Hai Robotics); Jean-Luc Laurans, Supply Chain Director North Asia (L'Oréal); Jakub Czaplicki, Fulfillment Factory Director North Asia (L'Oréal); Alan Liu, President of Greater China, Japan & Korea (Hai Robotics); Iris Gu, Key Accounts Manager (Hai Robotics) (Photo: Business Wire)
With an area of 46,000 square meters, this fulfillment center houses Hai's essential goods-to-person solution, HaiPick System 1, including 39 HaiPick A42 Multi-Layer Autonomous Case-handling Mobile Robots (ACR), as well as HaiPort and conveyor picking workstations. L'Oréal is now able to handle D2C (direct-to-consumer) orders with elevated flexibility, efficiency and scalability for L'Oréal, without compromising on intelligence and sustainability for its supply chain operations.
"We are delighted to be a part of L'Oréal's warehousing journey by supporting them with our ACR and goods-to-person technology. This marks a key moment in our partnership," Richie Chen, Founder and CEO of Hai Robotics said. "This new fulfillment center will facilitate supply chain transformation by improving operational efficiency, storage density and flexibility in tackling orders, ultimately elevating the experience for our customers who desire speed and convenience. We are proud to support L'Oréal in achieving their broader business objectives, and look forward to what the future has to bring."
Hai Robotics provides smart and superior ecommerce warehouse solutions for companies to address challenges in order fulfillment, error reduction, return processing etc. These solutions also enable companies to adjust operations flexibly to tackle peak season and adapt to rapid workflow changes. With Hai's automation solutions, warehouses experience increased storage density between 80%-400%, as well as enhanced outbound efficiency by 2.5 times.
The L'Oréal Suzhou SMART Fulfillment Center, equipped with superior automation technology and information systems, will be a key hub in the beauty brand's handling of D2C and B2B orders in Mainland China. It will allow L'Oréal to better support its commercial clients consisting of ecommerce platforms, offline retailers, as well as beauty salons. To learn more about our HaiPick systems, please visit https://www.hairobotics.com/products.
For more information on L’Oréal, please visit https://www.loreal.com/en/mediaroom.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240512209916/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment4.12.2025 14:00:00 CET | Press release
OXTEND-03™ (NCT06930625) is a Phase III, multi-center, randomized trial assessing the efficacy and safety of Debio 4126, the first and only octreotide formulation designed for quarterly (3-month) dosing Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company committed to establishing tomorrow’s standards of care in oncology and rare diseases, today announced that the first patient has been randomized in the OXTEND-03™ clinical trial. This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in adults with acromegaly who are currently maintained on somatostatin analogs. OXTEND-03™ is a global trial spanning approximately 75 sites across 21 countries, aiming to enroll around 120 patients. The primary goal of the trial is to confirm Debio 4126’s ability to maintain biochemical control of the disease while significantly
Visa Launches Global Art Collection to Elevate Creators and Celebrate the FIFA World Cup 26™4.12.2025 14:00:00 CET | Press release
Visa spotlights global illustrators and creative small businesses, teaming up with Pharrell Williams’ JOOPITER to accelerate creator growth. Visa today unveiled the first five pieces in its first-ever global art collection celebrating the cultural energy of the FIFA World Cup 26™. Featuring more than twenty artists from six continents, the collection reflects Visa’s belief that creativity drives commerce—and that today’s creators are the entrepreneurs shaping communities and culture around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204080105/en/ Darien Birks (Global) Visa debuted the first five pieces in the collection at an exclusive Miami showcase, “The Art of the Draw”, hosted by multidisciplinary creator KidSuper. The showcase featured the works of artists Darien Birks, Nathan Walker, Cesar Canseco, Ivan Roque, and Rafael Mayani that celebrate the culture and traditions of each host country and host cit
Parse Biosciences Launches Evercode Whole Blood Fixation4.12.2025 14:00:00 CET | Press release
New fixation method streamlines blood sample handling for translational research Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixation of whole blood directly at the point of collection. The technology eliminates the need for on-site PBMC isolation, specialized equipment, or trained personnel, allowing translational hematology and pharmaceutical research teams to seamlessly collect blood samples in real-world clinical settings for downstream single cell analysis. Traditional single cell RNA profiling workflows done in a translational setting require a compromise between processing fresh samples, which degrade rapidly and demand skilled handling, and using fixation approaches that capture only a partial transcriptome and cannot provide paired TCR sequences. Fresh PBMC isolation also requires complex workflows and specialized reagents. Everc
LTIMindtree Wins Two 2025 AWS Partner Awards at AWS re:Invent4.12.2025 13:45:00 CET | Press release
Recognized as Application Modernization Consulting Partner of the Year and Industry Partner of the Year - Travel and Hospitality winner LTIMindtree [NSE: LTIM, BSE: 540005], a leading global technology consulting and digital solutions provider, announced that it received the AWS 2025 Geography and Global Partner Awards, recognizing leaders around the globe who play key roles in helping clients drive innovation and build solutions on Amazon Web Services (AWS). LTIMindtree has been awarded Application Modernization Consulting Partner of the Year (Global) and Industry Partner of the Year - Travel and Hospitality. At the AWS re:Invent 2025 Partner Awards Gala, partners were recognized for their specialization, innovation, and collaboration, and for evolving business models that enable success on AWS while supporting their customers. LTIMindtree was recognized as: The Industry Partner of the Year - Travel and Hospitality: Recognized as a trusted transformation partner in Travel and Hospital
Stafford Establishes Timberland Continuation Fund at USD 1.2 billion4.12.2025 10:53:00 CET | Press release
This marks Stafford’s second timberland fund at over USD 1 Billion in 2025, backed by strong existing investor support and new capital commitments from global institutional investors Stafford Capital Partners (“Stafford”) today announced it has established a USD 1.2 billion continuation vehicle, the Stafford International Timberland Continuation Fund (The Continuation Fund or The Fund), marking a significant milestone in the firm’s strategic management of its timberland holdings. The Continuation Fund is a "roll-up" of three of Stafford’s existing core timberland funds – Stafford International Timberland funds VI, VII and VIII – into a new perpetual fund that will hold 74 high-quality core timberland assets. The fully-deployed portfolio took Stafford seven years to construct and holds interests in over 6.3m acres of commercial timberland in the USA, New Zealand, Australia and Latin America. This includes a number of assets that are seen as key strategic holdings in these regions where
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom